Wave Life Sciences Ltd.
About Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $42.7M
- Net income
- -$204.4M
- Total assets
- $638.5M
- Market cap
- $1.1B
- Operating margin
- -504.1%
- Net margin
- -478.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $42.7M
- Operating expenses
- $258.1M
- Operating income
- -$215.4M
- Income tax
- $0
- Net income
- -$204.4M
- EPS (basic)
- $-1.21
- EPS (diluted)
- $-1.21
Balance sheet
- Total assets
- $638.5M
- Current assets
- $614.8M
- Total liabilities
- $112.3M
- Current liabilities
- $95.1M
- Shareholders’ equity
- $518.4M
Cash flow
- Operating cash flow
- -$187.5M
- Investing cash flow
- -$718.0K
- Financing cash flow
- $488.2M
- Net cash flow
- $300.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.1B
- EPS (diluted)
- $-1.21
- Shares outstanding
- 193.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 11, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $204.4M in FY2025.
- Revenue grew 4% from FY2021 to FY2025.
- Trading 73% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Wave Life Sciences Ltd..
Write a review
News about Wave Life Sciences Ltd.
News & sentiment via Polygon.io
